Articles by Adeline Siew, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Adeline Siew, PhD

Adeline Siew, PhD


Adeline Siew is the editor of Pharmaceutical Technology Europe. Adeline Siew joined the editorial team of Pharmaceutical Technology and BioPharm International in 2012. She has a pharmacy degree from the University of Strathclyde and a PhD in Pharmaceutics (Drug Delivery) from the School of Pharmacy, University of London, where she also did her post doctorate research. She previously worked as an editor at IMS Health and BioMed Central before joining Advanstar's Pharm Sciences group.

Articles
Bioavailability Enhancement with Lipid-Based Drug-Delivery Systems
August 2, 2014

Experts from Capsugel and Catalent discuss the rationale of using lipid-based formulations to improve the oral bioavailability of poorly soluble drugs.

Tracking the Pulse of the Pharmaceutical Industry
August 1, 2014

Pharmaceutical Technology Europe marks its 25th anniversary.

Advances in Controlled-Release Drug Delivery
June 2, 2014

Industry experts share their perspectives on key advances in controlled-release drug delivery and future innovations in this arena.

Freeze Drying Protein Formulations
May 2, 2014

Common challenges and key considerations when developing a freeze-drying cycle for protein pharmaceuticals.

Extractables and Leachables Testing
May 2, 2014

Industry experts discuss how extractables and leachables studies are designed using a risk-based approach.

Navigating the Regulatory Landscape of Combination Products
April 2, 2014

Mark D. Kramer talks about combination products from a regulatory perspective and explains the implications of FDA's final rule on current GMP requirements for combination products.

Tackling challenges in the development of fixed-dose combinations
April 2, 2014

Anil Kane from Patheon spoke to Pharmaceutical Technology about the challenges in the development of FDCs and discussed how to integrate quality-by-design (QbD) in the manufacturing process of FDCs.

Current issues with nanomedicines
March 2, 2014

Despite the progress made in nanomedicine development, there are several issues that remain unresolved. Raj Bawa, PhD, provides insight.

Characterization of nanomedicines
March 2, 2014

Nanomedicines can offer promising benefits in the diagnosis and treatment of diseases but there are still concerns about the safety and quality of these therapeutics partly because of the lack of clear regulatory guidance. Scott McNeil, PhD, director of the Nanotechnology Characterization Laboratory (NCL), spoke with Pharmaceutical Technology about nanomedicine characterization.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here